BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 28332704)

  • 1. Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study.
    Verdoux H; Pambrun E; Tournier M; Bezin J; Pariente A
    Acta Psychiatr Scand; 2017 May; 135(5):429-438. PubMed ID: 28332704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotic long-acting injections: A community-based study from 2007 to 2014 of prescribing trends and characteristics associated with initiation.
    Verdoux H; Pambrun E; Tournier M; Bezin J; Pariente A
    Schizophr Res; 2016 Dec; 178(1-3):58-63. PubMed ID: 27624680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.
    Kishimoto T; Robenzadeh A; Leucht C; Leucht S; Watanabe K; Mimura M; Borenstein M; Kane JM; Correll CU
    Schizophr Bull; 2014 Jan; 40(1):192-213. PubMed ID: 23256986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies.
    Haddad PM; Taylor M; Niaz OS
    Br J Psychiatry Suppl; 2009 Nov; 52():S20-8. PubMed ID: 19880913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
    Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
    Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence, health care utilization, and costs between long-acting injectable and oral antipsychotic medications in South Carolina Medicaid beneficiaries with schizophrenia.
    Cai C; Kozma C; Patel C; Benson C; Yunusa I; Zhao P; Reeder G; Narasimhan M; Bank RL
    J Manag Care Spec Pharm; 2024 Jun; 30(6):549-559. PubMed ID: 38824623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics.
    Mahlich J; Olbrich K; Wilk A; Wimmer A; Wolff-Menzler C
    Clin Drug Investig; 2021 Jan; 41(1):99-113. PubMed ID: 33331979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics.
    Misawa F; Kishimoto T; Hagi K; Kane JM; Correll CU
    Schizophr Res; 2016 Oct; 176(2-3):220-230. PubMed ID: 27499361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia.
    Huang CY; Fang SC; Shao YJ
    JAMA Netw Open; 2021 May; 4(5):e218810. PubMed ID: 33974056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Neuroleptic Malignant Syndrome With Depot Versus Oral Antipsychotics: A Systematic Review and Pooled, Patient-Level Analysis of 662 Case Reports.
    Guinart D; Misawa F; Rubio JM; Pereira J; Sharma H; Schoretsanitis G; Kane JM; Correll CU
    J Clin Psychiatry; 2020 Nov; 82(1):. PubMed ID: 33238083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to rehospitalization in patients with bipolar mania discharged on long-acting injectable or oral antipsychotics.
    Lin CH; Chan HY; Hsu CC; Chen FC
    J Affect Disord; 2021 Jan; 279():292-298. PubMed ID: 33096327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016-March 2019.
    Peters L; Krogmann A; von Hardenberg L; Bödeker K; Nöhles VB; Correll CU
    Curr Psychiatry Rep; 2019 Nov; 21(12):124. PubMed ID: 31745659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics on Time to Rehospitalization Within 1 Year of Discharge in Elderly Patients With Schizophrenia.
    Lin CH; Chen FC; Chan HY; Hsu CC
    Am J Geriatr Psychiatry; 2020 Jan; 28(1):23-30. PubMed ID: 31481273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics.
    Lin CH; Chen FC; Chan HY; Hsu CC
    Int J Neuropsychopharmacol; 2019 Sep; 22(9):541-547. PubMed ID: 31260538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trend survey on adverse event profiles of antipsychotic long-acting injections and oral agents using the Japanese adverse drug event report database.
    Hatano M; Kamei H; Shimato A; Yamada S; Iwata N
    Psychiatry Res; 2020 Sep; 291():113249. PubMed ID: 32603929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years.
    Patel MX; Haddad PM; Chaudhry IB; McLoughlin S; Husain N; David AS
    J Psychopharmacol; 2010 Oct; 24(10):1473-82. PubMed ID: 19477883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of long-acting injectable
    Vita G; Tavella A; Ostuzzi G; Tedeschi F; De Prisco M; Segarra R; Solmi M; Barbui C; Correll CU
    Ther Adv Psychopharmacol; 2024; 14():20451253241257062. PubMed ID: 38831918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.